{"nctId":"NCT00825812","briefTitle":"Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)","startDateStruct":{"date":"2010-01"},"conditions":["Anesthesia, General","Neuromuscular Blockade"],"count":308,"armGroups":[{"label":"Sugammadex in Caucasian Subjects","type":"EXPERIMENTAL","interventionNames":["Drug: Sugammadex"]},{"label":"Neostigmine in Caucasian Subjects","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: neostigmine"]},{"label":"Sugammadex in Chinese Subjects","type":"EXPERIMENTAL","interventionNames":["Drug: Sugammadex"]},{"label":"Neostigmine in Chinese Subjects","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: neostigmine"]}],"interventions":[{"name":"Sugammadex","otherNames":["Org 25969, BridionÂ®"]},{"name":"neostigmine","otherNames":["Neostigmine with atropine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n-Subjects who are willing to provide informed consent; be between 18 and 64 years old; are American Society of Anaesthesiology (ASA) class 1-3 (extremes included); scheduled for elective surgery under general anesthesia, allowing stable neuromuscular monitoring, which requires neuromuscular blockade using rocuronium; be compliant with the dose/visit schedules, and use an accepted method of contraception (if applicable).\n\nFor China only: Subjects of Chinese descent born in China, never emigrated out of China and have a Chinese home address. For Europe only: Subjects of Caucasian descent born in Europe, never emigrated out of Europe and have a European home address.\n\nExclusion Criteria:\n\n-Subjects with expected difficult intubation, neuromuscular disorders affecting neuromuscular blockade, significant renal/hepatic dysfunction, use of a tourniquet, (family) history of malignant hyperthermia, allergy to general anesthesia medications, contraindication to study drugs, breast feeding, pregnant, participation in previous or new trials, a clinically significant condition that may interfere with the trial, or membership in the (family of) study/sponsor staff.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time From Start of Administration of Investigational Medicinal Product (IMP) to Recovery of the T4/T1 Ratio to 0.9.","description":"Neuromuscular functioning was monitored by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation was to continue until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached \\>= 0.9. The greater the T4/T1 ratio the greater the recovery from neuromuscular blockade, with a value of 1.0 representing full recovery.\n\nThe primary analysis was the comparison between sugammadex \\& neostigmine among Chinese subjects; other comparisons were secondary.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"6.7","spread":null},{"groupId":"OG002","value":"1.6","spread":null},{"groupId":"OG003","value":"9.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.7 and 0.8.","description":"Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. The greater the T4/T1 ratio the greater the recovery from neuromuscular blockade.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"3.4","spread":null},{"groupId":"OG002","value":"1.1","spread":null},{"groupId":"OG003","value":"4.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"4.6","spread":null},{"groupId":"OG002","value":"1.3","spread":null},{"groupId":"OG003","value":"6.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":29},"commonTop":["Incision site pain","Procedural pain","Pyrexia","Dizziness","Nausea"]}}}